Cipla inks pact with Eli Lilly to produce, sell COVID-19 treatment drug
PTI, May 10, 2021, 10:59 AM IST
New Delhi: Drug major Cipla on Monday said it has inked a pact with US-based Eli Lilly and Company to manufacture and produce baricitinib in the country for the treatment of COVID-19.
The Mumbai-based company said it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly for baricitinib.
Baricitinib has already received a restricted emergency use approval by the Central Drugs Standard Control Organisation (CDSCO), Ministry of Health, India, for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
This collaboration is a step further in the company”s efforts to enhance access to critical treatments for patients affected by the pandemic, Cipla said in a statement.
The company will leverage its extensive distribution footprint to make this therapy accessible to more patients and markets, it added.
“Through the pandemic, Cipla has been at the forefront of COVID care and our partnership with Lilly is a demonstration of our unwavering commitment to care towards patients impacted by COVID-19,” Cipla Ltd MD and Global CEO Umang Vohra noted.
Cipla had last year launched a generic version of antiviral drug remdesivir to treat COVID-19 patients. The drug firm had also introduced antibody detection kits for COVID-19 in the country under the brand name ”ELIFast” in partnership with KARWA Ltd, under the technology transfer from the Indian Council of Medical Research (ICMR).
Amid spiralling cases of COVID-19 in the country amid the second wave, drug firms have been collaborating to come out with drugs to treat the highly infectious disease.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
IndiGo flags higher inflationary environment, escalation in fuel, airport costs
Sensex rebounds 1,293 points, Nifty races to record high on value buying in bluechips
IDBI Bank privatisation: Security clearances in place, RBI’s nod expected soon
Hyundai ties up with Charge Zone for high-speed EV chargers
Stock markets fall for 4th day on selling in banking shares, STT hike
MUST WATCH
Latest Additions
Meat consignment: Legal action to be taken based on analysis report of species
Mamata walks out of Niti Aayog meet, says she was stopped midway in her speech
Teachers above 50 years of age exempted from ‘excess teacher’ transfers: Karnataka HC
Writ of ‘Shivaji Fan Club’ runs in Maharashtra, that of ‘Aurangzeb Fan Club’ in Gujarat: Raut
Olympics 2024: Athletes have every right to ask for personal coaches, says Vijender Singh
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.